Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5268425 | 0.93 | DPP4 (0.47) | DPP4 | |
| SCHEMBL5232731 | 0.93 | DPP4 (0.51) | DPP4 | |
| SCHEMBL5234496 | 0.92 | DPP4 (0.47) | DPP4 | |
| SCHEMBL5236353 | 0.87 | DPP4 (0.56) | DPP4 | |
| SCHEMBL5233362 | 0.86 | DPP4 (0.52) | DPP4GRM2 | |
| SCHEMBL5235279 | 0.85 | DPP4 (0.57) | DPP4GRM2 | |
| SCHEMBL5239931 | 0.85 | DPP4 (0.47) | DPP4GRM2 | |
| SCHEMBL5237115 | 0.84 | DPP4 (0.52) | DPP4GRM2 | |
| SCHEMBL5237127 | 0.84 | DPP4 (0.52) | DPP4GRM2 | |
| SCHEMBL5238387 | 0.82 | DPP4 (0.52) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | DPP4 2/4885GRM2 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.